Skip to main content

Advertisement

SpringerLink
Log in

i.v.-Immunglobuline bei chronischen idiopathischen Myositiden

  • BEITRAG ZUM SCHWERPUNKTTHEMA
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407

    Google Scholar 

  2. Burmester G-R, Buttgereit F (2001) Dermatomyositis—Polymyositis. In: Zeidler H, Zacher J, Hiepe F, editors. Interdisziplinäre klinische Rheumatologie. Springer, Berlin, S895–903

  3. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325(21):1487–1498

    Google Scholar 

  4. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (First of two parts). N Engl J Med 292(7):344–347

    CAS  PubMed  Google Scholar 

  5. Catoggio LJ (2003) Connective Tissue Disorders: Inflammatory Muscle Disease. Management. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology. Mosby, Edinburgh, pp 1555–1562

  6. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993–2000

    Article  CAS  PubMed  Google Scholar 

  7. WHO technical report (1989) Requirements for the collection, processing, and quality control of blood, blood components, and plasma derivatives. WHO technical Report Series No 786: Annex 4

    Google Scholar 

  8. Berger A, Doerr HW, Scharrer I, Weber B (1997) Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission. J Med Virol 53(1):25–30

    Google Scholar 

  9. Bjorkander J, Fasth A, Widell A (1996) Intravenous immunoglobulin and hepatitis C virus: the Scandinavian experience. Clin Ther 18:(Suppl B):73–82

    Google Scholar 

  10. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331(24):1607–1611

    Google Scholar 

  11. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ et al (1996) Hepatitis C virus infection associated with administration of intravenous immune globulin: A cohort study. JAMA 276(19):1563–1567

    Google Scholar 

  12. Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N et al (1997) Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 110(1):4–8

    Google Scholar 

  13. Flora K, Schiele M, Benner K, Montanaro A, Johnston W, Whitham R et al (1996) An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin. Ann Allergy Asthma Immunol 76(2):160–162

    Google Scholar 

  14. Gangneux JP, Traineau R, Tuveri R, Ravera N, Bureau C, Gluckman E et al (1996) Transmission of hepatitis C virus in allografted patients: use of viral genotyping as an epidemiological marker. Bone Marrow Transplant 18(6):1131–1133

    Google Scholar 

  15. Gomperts ED (1996) Gammagard and reported hepatitis C virus episodes. Clin Ther 18(Suppl B):3–8

    Google Scholar 

  16. Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA et al (1996) Outbreak of acute hepatitis C following the use of anti-hepatitis C virus-screened intravenous immunoglobulin therapy. Gastroenterology 110(4):1120–1126

    Google Scholar 

  17. Jonas MM, Baron MJ, Bresee JS, Schneider LC (1996) Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 98(2 (Pt 1):211–215

    Google Scholar 

  18. Lefrere JJ, Loiseau P, Martinot-Peignoux M, Mariotti M, Ravera N, Thauvin M et al (1996) Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion 36(5):394–397

    Google Scholar 

  19. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E (1997) Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 90(3):1309–1314

    Google Scholar 

  20. Widell A, Zhang YY, Andersson-Gare B, Hammarstrom L (1997) At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C. Transfusion 37(3):313–320

    Google Scholar 

  21. Yap PL, McOmish F, Webster AD, Hammarstrom L, Smith CI, Bjorkander J et al (1994) Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 21(3):455–460

    Google Scholar 

  22. Ballow M (2002) Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc (Wash) 42(3):458–459

    Google Scholar 

  23. Dodd RY (1996) Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Clin Exp Immunol 104 (Suppl 1):31–34

    Google Scholar 

  24. Tabor E (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39:1160–1168

    Google Scholar 

  25. Barin F (2000) Viruses and unconventional transmissible agents: update on transmission via blood. Transfus Clin Biol 7 (Suppl 1):5S–10S

    Google Scholar 

  26. Will RG, Kimberlin RH (1998) Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sang 75(3):178–180

    Google Scholar 

  27. Yap PL, Leaver HA, Gillon J (1998) Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Vox Sang 74(Suppl 2):131–134

    Google Scholar 

  28. Lacy CF, Armstrong LL, Goldman MP, Lance LL (2003) Drug Information Handbook, 11th ed. Hudson, Ohio, Lexi-Comp Inc

  29. Schiff RI (1986) Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev Infect Dis 8 (Suppl 4):S449–S456

    Google Scholar 

  30. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M et al (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50(2):398–402

    CAS  PubMed  Google Scholar 

  31. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349(9052):589–593

    Article  CAS  PubMed  Google Scholar 

  32. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41(6):789–796

    CAS  PubMed  Google Scholar 

  33. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315(6):341–347

    Google Scholar 

  34. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639

    Google Scholar 

  35. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M et al (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50(5):1273–1281

    CAS  PubMed  Google Scholar 

  36. van der Meché FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326(17):1123–1129

    PubMed  Google Scholar 

  37. Dalakas MC (1996) Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 104 (Suppl 1):55–60

    Google Scholar 

  38. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345(10):747–755

    Article  CAS  PubMed  Google Scholar 

  39. Wittstock M, Benecke R, Zettl UK (2003) Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 50(3):172–175

    Article  CAS  PubMed  Google Scholar 

  40. Buckley RH, Schiff RI (1991) The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325(2):110–117

    CAS  PubMed  Google Scholar 

  41. Bjorkander J, Hammarstrom L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LA (1987) Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 7(1):8–15

    Google Scholar 

  42. Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD (1994) Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 154(17):1985–1987

    Google Scholar 

  43. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ (1995) Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 25(2):228–234

    Google Scholar 

  44. Stahl M, Schifferli JA (1998) The renal risks of high-dose intravenous immunoglobulin treatment [editorial]. Nephrol Dial Transplant 13(9):2182–2185

    Google Scholar 

  45. US Food and Drug Administration. Important Drug Warning. http://www.fda.gov/cber/ltr/igivrenal.htm

  46. Brox AG, Cournoyer D, Sternbach M, Spurll G (1987) Hemolytic anemia following intravenous gamma globulin administration. Am J Med 82 (Suppl 3):633–635

    Google Scholar 

  47. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM (1992) Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 120(6):926–928

    Google Scholar 

  48. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ (1986) Hemolysis following intravenous immune globulin therapy. Transfusion 26(5):410–412

    Google Scholar 

  49. Nakamura S, Yoshida T, Ohtake S, Matsuda T (1986) Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol; 76(2–3):115–118

    Google Scholar 

  50. Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121(4):259–262

    Google Scholar 

  51. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP (1996) Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47(3):674–677

    PubMed  Google Scholar 

  52. Crouch ED, Watson LE (2002) Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura–a case report and literature review. Angiology 53(1):113–117

    PubMed  Google Scholar 

  53. Elkayam O, Paran D, Milo R, Davidovitz Y, Almoznino-Sarafian D, Zeltser D et al (2000) Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 59(1):77–80

    Article  CAS  PubMed  Google Scholar 

  54. Emerson GG, Herndon CN, Sreih AG (2002) Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 22(12):1638–1641

    Article  PubMed  Google Scholar 

  55. FDA: FDA Interim Statement Regarding Immune Globulin Intravenous (IGIV). http://www.fda.gov/cber/infosheets/igiv082702.htm

  56. Fisman DN, Smilovitch M (1997) Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 13(8):775–777

    CAS  PubMed  Google Scholar 

  57. Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75(1):83–85

    CAS  PubMed  Google Scholar 

  58. Okuda D, Flaster M, Frey J, Sivakumar K (2003) Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 60(11):1825–1826

    PubMed  Google Scholar 

  59. Struble EJ, Dice YG (2002) Intravenous immune globulin (IVIG) precipitating acute myocardial infarction. J Miss State Med Assoc 43(4):115

    Google Scholar 

  60. Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK et al (2003) Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 10(4):367–372

    Google Scholar 

  61. Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A et al (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirtyfive adult patients. Arthritis Rheum 46(2):467–474

    Article  CAS  PubMed  Google Scholar 

  62. Göttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B (2000) High-dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10(1):29–35

    CAS  PubMed  Google Scholar 

  63. Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M et al (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61(1):37–41

    Google Scholar 

  64. Soueidan SA, Dalakas MC (1993) Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 43(5):876–879

    Google Scholar 

  65. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S et al (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58(2):326

    Google Scholar 

  66. Mukunda BN, Dileep Kumar P, Smith HR (2001) Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis. Ann Intern Med 134(12):1156 (letter)

    Google Scholar 

  67. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT (1994) Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 44(8):1516–1518

    Google Scholar 

  68. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (1997) Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology 48(3):712–716

    CAS  PubMed  Google Scholar 

  69. Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56(3):323–327

    CAS  PubMed  Google Scholar 

  70. Walter MC, Lochmüller H, Töpfer M, Schlotter B, Reilich P, Schröder M et al (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247(1):22–28

    Article  CAS  PubMed  Google Scholar 

  71. Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA et al (1994) Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol 21(11):2143–2146

    Google Scholar 

  72. Downey ECJr, Woolley MM, Hanson V (1988) Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 123(9):1117–1120

    Google Scholar 

  73. Miller LC, Michael AF, Kim Y (1987) Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila) 26(11):561–566

    Google Scholar 

  74. Pachman LM (1990) Juvenile dermatomyositis: a clinical overview. Pediatrics in Review 12(4):117–125

    Google Scholar 

  75. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43(3):541–549

    Google Scholar 

  76. Quecedo E, Febrer I, Serrano G, Martinez-Aparicio A, Aliaga A (1996) Partial lipodystrophy associated with juvenile dermatomyositis: report of two cases. Pediatr Dermatol 13(6):477–482

    Google Scholar 

  77. Galeazzi M, Bellucci AM, Girardelli CR, Bono R, De Pita O, Puddu P (1996) Efficacy of intravenous immunoglobulin therapy in a case of juvenile dermatomyositis. Clin Rheumatol 15(2):215–216

    Google Scholar 

  78. Kokori H, Fotoulaki M, Giannakopoulou C, Hatzidaki E, Tantros S, Sbyrakis S (1999) Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int 41(6):696–697

    Google Scholar 

  79. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW (1987) Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 258(4):513–515

    Google Scholar 

  80. Breems DA, de Haas PW, Visscher F, Sabbe LJ, Busch HF, van Doorn PA (1993) Intravenously-administered immunoglobulin as first-choice agent in juvenile dermatomyositis. Ned Tijdschr Geneeskd 137(39):1979–1982

    Google Scholar 

  81. Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D (1994) Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 130(2):231–234

    Google Scholar 

  82. Morita R, Nakano K, Hirano Y, Izumi T, Hirayama Y, Suzuki H et al (1989) Dramatic effects of high-dose intravenous gammaglobulin in each patient with intractable dermatomyositis and polymyositis. No To Hattatsu 21(6):523–528

    Google Scholar 

  83. Schmidt K, Westenberger-Treumann M, Stadler R (1994) High dosage intravenous gamma globulin therapy in juvenile dermatomyositis. Hautarzt 45(12):854–857

    Google Scholar 

  84. Vedanarayanan V, Subramony SH, Ray LI, Evans OB (1995) Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol 13(4):336–339

    Google Scholar 

  85. Zifko U, Grisold W (1995) Dermatomyositis: Erfolgreiche Therapie mit hochdosierten intravenös applizierten 7S-Immunoglobulinen. Wien Klin Wochenschr 107(17):522–524

    Google Scholar 

  86. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM (1991) Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91(2):169–172

    Google Scholar 

  87. Samsone A, Dubowitz V (1995) Intravenous immunoglobulin in juvenile dermatomyositis—four year review of nine cases. Arch Dis Child 72(1):25–28

    Google Scholar 

  88. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM (2000) Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27(10):2498–2503

    CAS  PubMed  Google Scholar 

  89. Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51 (Suppl 5)(6 Suppl 5):S37–S45.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumaklinik für Kinder und Jugendliche, Gehfeldstr. 24, 82467, Garmisch-Partenkirchen, Germany

    H. Michels

  2. Universitätsklinikum Charité, Med. Klinik, Schwerpunkt Rheumatologie und Klinische Immunologie, Schumannstr. 20/21, 10117, Berlin, Germany

    G.-R. Burmester &  F. Buttgereit

Authors
  1. H. Michels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G.-R. Burmester
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Buttgereit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Michels.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michels, H., Burmester, GR. & Buttgereit, F. i.v.-Immunglobuline bei chronischen idiopathischen Myositiden. Z. Rheumatol. 64, 102–110 (2005). https://doi.org/10.1007/s00393-005-0695-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-005-0695-7

Search

Navigation